Clin Cancer Res: The efficacy of Pabosili's combined quercitojudan anti-treatment for HER2 plus advanced breast cancer.

The purpose of this study (PATRICIA study) is to evaluate Palbociclib's combined quercili and or no endocrine therapy for HER2-positive (plus) advanced breast cancer.
the study was a forward-looking, open-label, multi-center Phase II trial that recruited patients with advanced breast cancer who had previously received 2-4 lines of anti-HER2-based treatment.
be treated with Pabosili (200 mg/day, 2 weeks, suspended for 1 week).
the study was based on a two-stage Simon design with three queues: estrogen-positive (ER) negative (A-queue), ER-positive (B1-queue), and ER-positive-to-lysole (B2 queue).
ER-positive patients were randomly assigned to B1 or B2 queues.
end of the disease is a progress-free survival rate (PFS6) at 6 months.
secondary endpoints include safety and assessment of the PAM50 in-house subsype.
recruited a total of 71 patients (15 in queue A, 28 in queues B1 and B2).
PFS6 for A, B1 and B2 queues was 33.3 per cent (5/15), 42.8 per cent (12/28) and 46.4 per cent (13/28), respectively.
safety: 1-2 and 3-4 toxic reactions occurred in 97.7% and 84.4% of patients, respectively.
most common level 3-4 toxic reactions were a decrease in neutral granulocytes (66.4%) and a decrease in plateplates (11.3%).
59 cases (83.1%) tumors were included in the PAM50 analysis: Luminal subtypes were independently associated with longer progression-free survival, and the medium PFS of luminal subtype vs non-luminal subtypes was 10.6 vs 4.2 months(correction risk ratio of 0.40, p-0.003).
above, Pabosili combined quercetoju monoantigen is used in patients with previously treated ER-positive/HER2-positive PAM50 luminal A or B subtype advanced breast cancer with good prognostic prognostication and high tolerance.
.